{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:32:31Z","timestamp":1785148351729,"version":"3.55.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jtocrr.2025.100835","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T15:55:10Z","timestamp":1745250910000},"page":"100835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Retreatment With Nivolumab and Ipilimumab in Pleural Mesothelioma Following Disease Progression After a Durable Response: Case Series"],"prefix":"10.1016","volume":"6","author":[{"given":"Illaa","family":"Smesseim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus A.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2025.100835_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2025.100835_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2025.100835_bib3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.6004\/jnccn.2016.0087","article-title":"NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016","volume":"14","author":"Ettinger","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl","key":"10.1016\/j.jtocrr.2025.100835_bib4","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.jtho.2024.09.088","article-title":"OA18.04 Pembrolizumab plus lenvatinib in second-line pleural mesothelioma patients: a single arm Phase II study (PEMMELA Cohort 2)","volume":"19","author":"Douma","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100835_bib5","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.3390\/cancers15143564","article-title":"Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients\u2019 responders to a first course of ICI: a multicenter national retrospective study of the French group of skin cancers (Groupe de cancerologie cutanee, GCC)","volume":"15","author":"Nardin","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2025.100835_bib6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtocrr.2025.100835_bib7","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and efficacy of Re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtocrr.2025.100835_bib8","doi-asserted-by":"crossref","first-page":"32298","DOI":"10.18632\/oncotarget.25949","article-title":"Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer","volume":"9","author":"Niki","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtocrr.2025.100835_bib9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00280-019-03926-y","article-title":"Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer","volume":"84","author":"Mouri","year":"2019","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364325000517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364325000517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T17:33:36Z","timestamp":1751650416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364325000517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2666364325000517"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100835","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retreatment With Nivolumab and Ipilimumab in Pleural Mesothelioma Following Disease Progression After a Durable Response: Case Series","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100835","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100835"}}